The United States is worst hit by the pandemic, with confirmed cases higher than any other country. Therefore, the country is focusing on every aspect to put up a fight against the disease. To help such a fight, the country is about to undergo a large scale drug trial on the antimalarial drug called Hydroxychloroquine. The trial is mainly sponsored by the Switzerland pharmaceutical giant Novartis. In a recent statement, the company said that it has signed an agreement with the FDA to start its initial clinical trial. This trial will include a total of 400 patients, which will help experts evaluate the reliability of the drug in fighting the disease.
The drug rose to prominence after its success in treating COVID-19 patients in France and China. From then on, the drug is used widely all over the globe to combat the global pandemic. Although there has been a mixed debate about the drug’s effectiveness, many countries still have used it based on its reported positive consequences. However, we need larger trials to determine the real effectiveness of the drug. We already saw one such large trial started by the WHO for this drug. Additionally, this trial will explore more of the benefits of the drug and probably can become a game-changer, as stated by the President.
One should also note that we do not have a cure for the disease, and it may possibly take a while to find a cure. Therefore, we need many trials like this to lead us to the possibility of finding a cure.
The Hydroxychloroquine drug trial
The trail is said to happen in a few weeks in dozen sites situated around the country. The drugs are said to be provided by Sandoz, which is the generics and biosimilars arm of the company (Novartis). The trail is also said to happen in three groups, with the first being with the drug alone, second with a combination of the drug with antibiotic azithromycin, and third, being a placebo medicine.
In addition to all this, Novartis also said that the people affected will continue to receive standard COVID-19 treatment. Also, Novartis is said to co-sponsor the clinical trial to study about ruxolitinib and canakinumab for patients affected with COVID-19. With the U.S. already stocking 29 million pills for future use, the results of the trial will help us answer many questions in the days to come.
Join our writing team and develop your writing skills, as you see your articles featured on Apple News, Google News, and all around the world. Subscribe to our newsletter, What Just Happened, where we dive deep into the hottest topics from the week!